머스트바이오는 혁신적인 다중특이 면역항암제 개발에 전념하고 있습니다.

  • Research
Program Target Indication POC Candidate Pre-clinical Clinical
MB5029 αPD-1 x IL-2v
Bi-specific fusion protein
Solid tumors
  • POC
  • Candidate
  • Pre-clinical
  • Clinical

MB4 αPD-1 x IL-2v x TAA
Tri-specific fusion protein
Solid tumors
  • POC
  • Candidate
  • Pre-clinical
  • Clinical

MB7 αPD-1 x IL-21v x TAA
Tri-specific fusion protein
Solid tumors
  • POC
  • Candidate
  • Pre-clinical
  • Clinical

MB6 αCD3 x TAA x TAA
Tri-specific fusion protein
Solid tumors
  • POC
  • Candidate
  • Pre-clinical
  • Clinical